Chimerix Inc (CMRX) Expected to Post Quarterly Sales of $810,000.00

Wall Street brokerages expect that Chimerix Inc (NASDAQ:CMRX) will report sales of $810,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Chimerix’s earnings. The highest sales estimate is $1.00 million and the lowest is $500,000.00. Chimerix reported sales of $1.98 million during the same quarter last year, which indicates a negative year-over-year growth rate of 59.1%. The firm is expected to report its next earnings report on Thursday, March 1st.

According to Zacks, analysts expect that Chimerix will report full-year sales of $810,000.00 for the current year, with estimates ranging from $2.65 million to $3.65 million. For the next fiscal year, analysts anticipate that the company will post sales of $3.75 million per share, with estimates ranging from $1.00 million to $6.25 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Chimerix.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $0.81 million.

Several equities analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Chimerix in a report on Friday. They set a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Friday, November 10th. Finally, ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Chimerix presently has a consensus rating of “Hold” and an average target price of $7.06.

In related news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC raised its holdings in shares of Chimerix by 131.8% in the 3rd quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock worth $869,000 after acquiring an additional 94,108 shares during the last quarter. Nationwide Fund Advisors raised its holdings in shares of Chimerix by 70.3% in the 3rd quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 24,994 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Chimerix by 112.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock worth $1,055,000 after acquiring an additional 106,267 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Chimerix in the 3rd quarter worth about $428,000. Finally, State Street Corp raised its holdings in shares of Chimerix by 7.3% in the 2nd quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock worth $4,515,000 after acquiring an additional 56,600 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Chimerix (NASDAQ CMRX) opened at $4.70 on Friday. Chimerix has a fifty-two week low of $4.17 and a fifty-two week high of $6.64. The firm has a market cap of $222.45, a PE ratio of -3.29 and a beta of 1.42.

ILLEGAL ACTIVITY NOTICE: “Chimerix Inc (CMRX) Expected to Post Quarterly Sales of $810,000.00” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/04/chimerix-inc-cmrx-expected-to-post-quarterly-sales-of-810000-00.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply